Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include ...

Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for ...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in ...

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart ...

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

DALLAS Despite scientific advances in cardiovascular care, people in living in rural areas and other communities with ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with amyloid light-chain (AL) amyloidosis ...